Zydus teriparatide
Teriparatide biosimilar developed by Cadila Healthcare (Zydus Lifesciences). Reference product Forsteo (Forteo in the United States).
About Zydus teriparatide
Zydus, then Cadila Healthcare, received its teriparatide permission in India in August 2012, a week after USV, in vial and cartridge forms.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Zydus teriparatide holds an approval, these are the other teriparatide biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 3 | Enzene Biosciences (Enzene Biosciences teriparatide), Intas Pharmaceuticals (Sondelbay / Intas teriparatide), USV (USV teriparatide) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Zydus Lifesciences: Exemptia / Cadalimab, Nufymco, Zydus aflibercept, Zydus bevacizumab, Zydus epoetin, Zydus follitropin alfa, Zydus peginterferon alfa-2b, Zydus pertuzumab, Zydus rituximab, Zydus trastuzumab.
Chronology
- CDSCOAug 2012CDSCO permission granted
Sources
S014CDSCO, permissions granted in Form 46 and 46A, to 2019 Primary (regulator)
Planning teriparatide biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant